{
    "clinical_study": {
        "@rank": "158061", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 12 subjects (male and female) with moderate hepatic impairment"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 12 healthy subjects (male and female)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the pharmacokinetics (PK) and safety of multiple doses of\n      lumacaftor in combination with ivacaftor in subjects with moderate hepatic impairment."
        }, 
        "brief_title": "Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hepatic Impairment", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Group A: Subjects with Moderate Hepatic Impairment\n\n          -  Male and female 18 to 65 years of age (inclusive)\n\n          -  Satisfy the criteria for moderate hepatic impairment defined as a Child Pugh total\n             score of 7 to 9 (Child Pugh Class B) at the Screening Visit\n\n          -  Willing and able to comply with schedule visits, treatment, laboratory tests, and\n             contraceptive guidelines.\n\n        Group B: Healthy subjects\n\n          -  Male and female 18 to 65 years of age (inclusive)\n\n          -  Healthy subjects with no clinically relevant abnormalities identified by a detailed\n             medical history, complete physical examination, including blood pressure and pulse\n             rate measurement, standard 12-lead ECG, and clinical laboratory tests\n\n          -  Willing and able to comply with schedule visits, treatment, laboratory tests,\n             contraceptive guidelines and other study procedures\n\n        Exclusion Criteria:\n\n        Group A: Subjects with Moderate Hepatic Impairment\n\n          -  History of any illness that, in the opinion of the investigator, might confound the\n             results of the study or pose an additional risk in administering study drug(s) to the\n             subject\n\n          -  Have fluctuating or rapidly deteriorating hepatic function by history or as indicated\n             by significant variations in or worsening of clinical and/or laboratory signs of\n             hepatic impairment within 6 months before the Screening Visit\n\n          -  Other causes of hepatic impairment not related to parenchymal disorder and/or disease\n             of the liver\n\n          -  Severe hepatic encephalopathy\n\n          -  Type 1 diabetes mellitus or evidence of poorly controlled type 2 diabetes\n\n          -  Hepatocellular carcinoma, HIV, hepatitis B/C\n\n          -  Significant renal dysfunction\n\n          -  Solid organ or bone marrow transplantation\n\n          -  History of regular alcohol consumption, drug abuse or regular smoking\n\n        Group B: Healthy subjects\n\n          -  History of any illness that, in the opinion of the investigator, might confound the\n             results of the study or pose an additional risk in administering study drug(s) to the\n             subject\n\n          -  History of regular alcohol consumption, drug abuse or regular smoking"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888393", 
            "org_study_id": "VX13-809-010"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B"
            ], 
            "intervention_name": "lumacaftor 200 mg q12h + ivacaftor 250 mg q12h", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "pharmacokinetics, hepatic impairment", 
        "lastchanged_date": "November 18, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Slovakia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open Label Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "The Czech Republic: State Institute of Drug Control", 
                "Slovakia: State Institute of Drug Control"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Lumacaftor pharmacokinetic parameters, including Cmax, tmax, AUC, Vd, CL/F", 
                "safety_issue": "No", 
                "time_frame": "16 days"
            }, 
            {
                "measure": "Ivacaftor pharmacokinetic parameters, including Cmax, tmax, AUC, Vd, CL/F", 
                "safety_issue": "No", 
                "time_frame": "16 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888393"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Lumacaftor metabolites pharmacokinetic parameters, including Cmax and AUC", 
                "safety_issue": "No", 
                "time_frame": "16 days"
            }, 
            {
                "measure": "Ivacaftor metabolites pharmacokinetic parameters including Cmax, tmax, AUC", 
                "safety_issue": "No", 
                "time_frame": "16 days"
            }, 
            {
                "measure": "Safety and tolerability as mentioned by adverse events, clinical laboratory values, standard electrocardiograms, Vital signs and pulse oximetry", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }
        ], 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}